Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.032
Sell
RSI(14)
40.685
Neutral
STOCH(KDJ)(9,3,3)
30.847
Neutral
ATR(14)
0.133
Low Volatility
CCI(14)
-95.431
Neutral
Williams %R
85.000
Oversold
TRIX(12,20)
-0.397
Sell
StochRSI(14)
30.396
Sell
Search
Century Therapeutics Inc
IPSCAdd to Watchlist
2.020USD
-0.170-7.76%
Close 07-31 16:00（ET）Quotes delayed by 15 min
364.32MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-7.76%
5 Days
-4.27%
1 Month
-16.87%
6 Months
+9.78%
Year to Date
+103.06%
1 Year
+279.77%
Key Figures
2.180Open
2.180High
448.02KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.25%Turnover Ratio
2.190Prev. Close
2.020Low
665.95KTurnover
LossP/E Static
1.37P/B
0.00%Div Yield TTM
-33.57%ROA
3.04052wk High
0.65Volume Ratio
-126.57MNet Profit
180.10MShares
-1.1126EPS TTM
1.56Beta
-42.67%ROE
0.43552wk Low
7.31%Amplitude
100.00%Gross Margin
364.32MMarket Cap
-1.54Reward/Risk
5.68%Risk Rate
TradingKey Stock Score of Century Therapeutics Inc
Currency: USD Updated: 2026-07-31Key Insights
Century Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 80 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.12.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Century Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Century Therapeutics Inc Highlights
StrengthsRisks
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 4784.30% year-on-year.
Fairly Valued
The company’s latest PE is -1.82, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 114.13M shares, increasing 37.39% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 5.85M shares of this stock.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
5.120
Target Price
+153.47%
Upside Space
Century Therapeutics Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
6
analysts
Buy
Current Rating
5.120
Target Price
+153.47%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Century Therapeutics Inc
IPSC
6
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
2.074
Sell
MA10
2.123
Sell
MA20
2.197
Sell
MA50
2.244
Sell
MA100
2.277
Sell
MA200
1.764
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Century Therapeutics Inc Info
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Ticker SymbolIPSC
CompanyCentury Therapeutics Inc
CEOPfeiffenberger (Brent)
Websitehttps://www.centurytx.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52785.200
+407.200 (+0.78%)
28548.400
+387.500 (+1.38%)
7537.100
+62.000 (+0.83%)
14665.000
-84.000 (-0.57%)
63688.000
+836.000 (+1.33%)
6409.700
+44.300 (+0.70%)
78.832
-7.102 (-8.26%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4069.030
+27.600 (+0.68%)
FAQs
What is the current price of Century Therapeutics Inc (IPSC)?
The current price of Century Therapeutics Inc (IPSC) is 2.02.
What is the symbol of Century Therapeutics Inc?
The ticker symbol of Century Therapeutics Inc is IPSC.
What is the 52-week high of Century Therapeutics Inc?
The 52-week high of Century Therapeutics Inc is 3.04.
What is the 52-week low of Century Therapeutics Inc?
The 52-week low of Century Therapeutics Inc is 0.43.
What is the market capitalization of Century Therapeutics Inc?
The market capitalization of Century Therapeutics Inc is 364.32M.
Is Century Therapeutics Inc (IPSC) currently rated as Buy, Hold, or Sell?
According to analysts, Century Therapeutics Inc (IPSC) has an overall rating of Buy, with a price target of 5.12.
What is the Earnings Per Share (EPS TTM) of Century Therapeutics Inc (IPSC)?
The Earnings Per Share (EPS TTM) of Century Therapeutics Inc (IPSC) is -0.11.